{"id":54629,"date":"2023-03-08T14:05:21","date_gmt":"2023-03-08T13:05:21","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/astria-therapeutics-to-report-fourth-quarter-full-year-2022-financial-results-and-recent-corporate-developments-on-wednesday-march-22nd\/"},"modified":"2023-03-08T14:05:21","modified_gmt":"2023-03-08T13:05:21","slug":"astria-therapeutics-to-report-fourth-quarter-full-year-2022-financial-results-and-recent-corporate-developments-on-wednesday-march-22nd","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/astria-therapeutics-to-report-fourth-quarter-full-year-2022-financial-results-and-recent-corporate-developments-on-wednesday-march-22nd\/","title":{"rendered":"Astria Therapeutics to Report Fourth Quarter\/Full Year 2022 Financial Results and Recent Corporate Developments on Wednesday, March 22nd"},"content":{"rendered":"
\n

BOSTON–(BUSINESS WIRE)–Astria Therapeutics, Inc.<\/a> (NASDAQ:ATXS) a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, will report fourth quarter\/full year 2022 financial results before the Nasdaq Global Market open on Wednesday, March 22, 2023. Jill C. Milne, Ph.D., Chief Executive Officer, will host a conference call and webcast at 8:30am ET to provide an update on corporate developments and to discuss fourth quarter and full year 2022 financial results.\n<\/p>\n

<\/a><\/p>\n

\nWebcast Information:
\n
<\/b>Interested parties may join the webcast via the Investors section of the Astria website, www.astriatx.com<\/a> or with the following link: https:\/\/lifescievents.com\/event\/astria-therapeutics-event\/<\/a>.\n<\/p>\n

\nPlease connect to the webcast several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be required. The webcast will be archived for 90 days.\n<\/p>\n

\nAbout Astria Therapeutics:
\n
<\/b>Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Learn more about our company on our website, www.astriatx.com<\/a>, or follow us on Twitter and Instagram @AstriaTx and on Facebook and LinkedIn.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor relations:<\/b>
Andrea Matthews
\n
investors@astriatx.com<\/a>\n<\/p>\n

\nMedia:<\/b>
Elizabeth Higgins
\n
media@astriatx.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

BOSTON–(BUSINESS WIRE)–Astria Therapeutics, Inc. (NASDAQ:ATXS) a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, will report fourth quarter\/full year 2022 financial results before the Nasdaq Global Market open on Wednesday, March 22, 2023. Jill C. Milne, Ph.D., Chief Executive … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-54629","6":"format-standard","7":"category-industry"},"yoast_head":"\nAstria Therapeutics to Report Fourth Quarter\/Full Year 2022 Financial Results and Recent Corporate Developments on Wednesday, March 22nd - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/astria-therapeutics-to-report-fourth-quarter-full-year-2022-financial-results-and-recent-corporate-developments-on-wednesday-march-22nd\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Astria Therapeutics to Report Fourth Quarter\/Full Year 2022 Financial Results and Recent Corporate Developments on Wednesday, March 22nd - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"BOSTON–(BUSINESS WIRE)–Astria Therapeutics, Inc. (NASDAQ:ATXS) a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, will report fourth quarter\/full year 2022 financial results before the Nasdaq Global Market open on Wednesday, March 22, 2023. Jill C. Milne, Ph.D., Chief Executive ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/astria-therapeutics-to-report-fourth-quarter-full-year-2022-financial-results-and-recent-corporate-developments-on-wednesday-march-22nd\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-08T13:05:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230308005098\/en\/1732416\/21\/MicrosoftTeams-image.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/astria-therapeutics-to-report-fourth-quarter-full-year-2022-financial-results-and-recent-corporate-developments-on-wednesday-march-22nd\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/astria-therapeutics-to-report-fourth-quarter-full-year-2022-financial-results-and-recent-corporate-developments-on-wednesday-march-22nd\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Astria Therapeutics to Report Fourth Quarter\\\/Full Year 2022 Financial Results and Recent Corporate Developments on Wednesday, March 22nd\",\"datePublished\":\"2023-03-08T13:05:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/astria-therapeutics-to-report-fourth-quarter-full-year-2022-financial-results-and-recent-corporate-developments-on-wednesday-march-22nd\\\/\"},\"wordCount\":254,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/astria-therapeutics-to-report-fourth-quarter-full-year-2022-financial-results-and-recent-corporate-developments-on-wednesday-march-22nd\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230308005098\\\/en\\\/1732416\\\/21\\\/MicrosoftTeams-image.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/astria-therapeutics-to-report-fourth-quarter-full-year-2022-financial-results-and-recent-corporate-developments-on-wednesday-march-22nd\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/astria-therapeutics-to-report-fourth-quarter-full-year-2022-financial-results-and-recent-corporate-developments-on-wednesday-march-22nd\\\/\",\"name\":\"Astria Therapeutics to Report Fourth Quarter\\\/Full Year 2022 Financial Results and Recent Corporate Developments on Wednesday, March 22nd - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/astria-therapeutics-to-report-fourth-quarter-full-year-2022-financial-results-and-recent-corporate-developments-on-wednesday-march-22nd\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/astria-therapeutics-to-report-fourth-quarter-full-year-2022-financial-results-and-recent-corporate-developments-on-wednesday-march-22nd\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230308005098\\\/en\\\/1732416\\\/21\\\/MicrosoftTeams-image.jpg\",\"datePublished\":\"2023-03-08T13:05:21+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/astria-therapeutics-to-report-fourth-quarter-full-year-2022-financial-results-and-recent-corporate-developments-on-wednesday-march-22nd\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/astria-therapeutics-to-report-fourth-quarter-full-year-2022-financial-results-and-recent-corporate-developments-on-wednesday-march-22nd\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/astria-therapeutics-to-report-fourth-quarter-full-year-2022-financial-results-and-recent-corporate-developments-on-wednesday-march-22nd\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230308005098\\\/en\\\/1732416\\\/21\\\/MicrosoftTeams-image.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230308005098\\\/en\\\/1732416\\\/21\\\/MicrosoftTeams-image.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/astria-therapeutics-to-report-fourth-quarter-full-year-2022-financial-results-and-recent-corporate-developments-on-wednesday-march-22nd\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Astria Therapeutics to Report Fourth Quarter\\\/Full Year 2022 Financial Results and Recent Corporate Developments on Wednesday, March 22nd\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Astria Therapeutics to Report Fourth Quarter\/Full Year 2022 Financial Results and Recent Corporate Developments on Wednesday, March 22nd - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/astria-therapeutics-to-report-fourth-quarter-full-year-2022-financial-results-and-recent-corporate-developments-on-wednesday-march-22nd\/","og_locale":"en_US","og_type":"article","og_title":"Astria Therapeutics to Report Fourth Quarter\/Full Year 2022 Financial Results and Recent Corporate Developments on Wednesday, March 22nd - Pharma Trend","og_description":"BOSTON–(BUSINESS WIRE)–Astria Therapeutics, Inc. (NASDAQ:ATXS) a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, will report fourth quarter\/full year 2022 financial results before the Nasdaq Global Market open on Wednesday, March 22, 2023. Jill C. Milne, Ph.D., Chief Executive ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/astria-therapeutics-to-report-fourth-quarter-full-year-2022-financial-results-and-recent-corporate-developments-on-wednesday-march-22nd\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-08T13:05:21+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230308005098\/en\/1732416\/21\/MicrosoftTeams-image.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/astria-therapeutics-to-report-fourth-quarter-full-year-2022-financial-results-and-recent-corporate-developments-on-wednesday-march-22nd\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/astria-therapeutics-to-report-fourth-quarter-full-year-2022-financial-results-and-recent-corporate-developments-on-wednesday-march-22nd\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Astria Therapeutics to Report Fourth Quarter\/Full Year 2022 Financial Results and Recent Corporate Developments on Wednesday, March 22nd","datePublished":"2023-03-08T13:05:21+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/astria-therapeutics-to-report-fourth-quarter-full-year-2022-financial-results-and-recent-corporate-developments-on-wednesday-march-22nd\/"},"wordCount":254,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/astria-therapeutics-to-report-fourth-quarter-full-year-2022-financial-results-and-recent-corporate-developments-on-wednesday-march-22nd\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230308005098\/en\/1732416\/21\/MicrosoftTeams-image.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/astria-therapeutics-to-report-fourth-quarter-full-year-2022-financial-results-and-recent-corporate-developments-on-wednesday-march-22nd\/","url":"https:\/\/pharma-trend.com\/en\/astria-therapeutics-to-report-fourth-quarter-full-year-2022-financial-results-and-recent-corporate-developments-on-wednesday-march-22nd\/","name":"Astria Therapeutics to Report Fourth Quarter\/Full Year 2022 Financial Results and Recent Corporate Developments on Wednesday, March 22nd - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/astria-therapeutics-to-report-fourth-quarter-full-year-2022-financial-results-and-recent-corporate-developments-on-wednesday-march-22nd\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/astria-therapeutics-to-report-fourth-quarter-full-year-2022-financial-results-and-recent-corporate-developments-on-wednesday-march-22nd\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230308005098\/en\/1732416\/21\/MicrosoftTeams-image.jpg","datePublished":"2023-03-08T13:05:21+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/astria-therapeutics-to-report-fourth-quarter-full-year-2022-financial-results-and-recent-corporate-developments-on-wednesday-march-22nd\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/astria-therapeutics-to-report-fourth-quarter-full-year-2022-financial-results-and-recent-corporate-developments-on-wednesday-march-22nd\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/astria-therapeutics-to-report-fourth-quarter-full-year-2022-financial-results-and-recent-corporate-developments-on-wednesday-march-22nd\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230308005098\/en\/1732416\/21\/MicrosoftTeams-image.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230308005098\/en\/1732416\/21\/MicrosoftTeams-image.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/astria-therapeutics-to-report-fourth-quarter-full-year-2022-financial-results-and-recent-corporate-developments-on-wednesday-march-22nd\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Astria Therapeutics to Report Fourth Quarter\/Full Year 2022 Financial Results and Recent Corporate Developments on Wednesday, March 22nd"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54629","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=54629"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54629\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=54629"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=54629"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=54629"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}